|1.||Yacoub, Magdi H: 10 articles (01/2014 - 06/2003)|
|2.||Burniston, Jatin G: 6 articles (02/2007 - 11/2002)|
|3.||Goldspink, David F: 6 articles (02/2007 - 11/2002)|
|4.||Birks, Emma J: 5 articles (03/2014 - 08/2005)|
|5.||Barton, Paul J R: 5 articles (12/2010 - 08/2005)|
|6.||Felkin, Leanne E: 5 articles (12/2010 - 08/2005)|
|7.||Tan, Lip-Bun: 5 articles (11/2006 - 11/2002)|
|8.||Katoch, Surender S: 5 articles (06/2006 - 06/2003)|
|9.||Tachiyashiki, Kaoru: 4 articles (01/2013 - 06/2007)|
|10.||Imaizumi, Kazuhiko: 4 articles (01/2013 - 06/2007)|
|1.||Body Weight (Weight, Body)
10/01/1987 - "Although clenbuterol increased body weight gain, it did not alter feed consumption and, therefore, feed efficiency (g gain/g food) was improved. "
05/01/2015 - "Among the study equids, long-term low-dose clenbuterol administration resulted in significant decreases in body fat with no loss in body weight."
02/01/2007 - "In the present study, the chronic administration of clenbuterol (2 mg/kg body weight; 30 days) resulted in various ultrastructural changes in three different types of muscles, gastrocnemius, a mixed-fiber type; anterior latissimus dorsi (ALD), a predominantly fast-twitch type; and diaphragm, a largely oxidative-type. "
01/01/1991 - "2. Clenbuterol significantly increases mean gain of body weight and feed efficiency in all the studies realised, but much more effectively in animals of greater age/weight (200 g). "
01/01/2014 - "Groups 1 and 2 were administered clenbuterol at a dose of 16 and 48 μg/kg body weight (BW)/day, respectively. "
08/30/2005 - "During complete LV unloading, clenbuterol did not prevent myocardial atrophy but improved gene expression (SERCA2a, beta-MHC) and beta-adrenergic responsiveness and potentially prevented myocardial apoptosis. "
01/01/2014 - "Out of many pharmacological agents studied, only the selective beta2 agonist clenbuterol has been proved to have a significantly beneficial effect on unloading-induced atrophy. "
02/01/2013 - "These effects were caused by decreased basal stimulation of cardiomyocyte β2-adrenoceptor (AR), as atrophy was prevented by treatment of denervated mice with the β2-AR agonist clenbuterol. "
01/01/2012 - "Clenbuterol suppresses proteasomal and lysosomal proteolysis and atrophy-related genes in denervated rat soleus muscles independently of Akt."
01/01/2009 - "In situations such as this, the use of a β 2-adrenergic agonist such as clenbuterol (Cb) may be of benefit in preventing atrophy. "
12/01/1984 - "Clenbuterol significantly improved sex combined weight gain and feed efficiency, and 49-day weights for both sexes. "
12/01/1984 - "In Experiments 2 and 3, clenbuterol fed from 28 to 49 days of age significantly improved sex combined weight gain and feed efficiency and both male and female 49-day weights. "
11/01/1993 - "In female rats, clenbuterol caused a 48% increase in weight gain (P < .05), with improved feed efficiency (26%; P < .1) and increased muscle mass (9%; P < .1). "
05/01/2006 - "Clenbuterol-treated HF rats had increased weight gain and heart weights versus HF rats (p < 0.05). "
06/01/1995 - "Clenbuterol increased both weight gain and gastrocnemius muscle weight, with the latter response in entire and castrated male rats (+ 1.31 and + 1.17 g) being more than double that seen in entire and ovariectomized females (+ 0.58 and + 0.55 g). "
|4.||Chronic Obstructive Pulmonary Disease (COPD)
07/01/1994 - "A field study of 239 horses was conducted to determine the efficacy and safety of clenbuterol HCl, a beta 2-adrenergic bronchodilator, when administered incrementally to effect in the treatment of chronic obstructive pulmonary disease (COPD). "
08/01/2000 - "When administered intratracheally (90 microg/horse) to horses suffering from chronic obstructive pulmonary disease (COPD), clenbuterol had effects that were not significantly different from those of saline. "
07/01/1994 - "Clinical efficacy and safety of clenbuterol HCl when administered to effect in horses with chronic obstructive pulmonary disease (COPD)."
11/18/1989 - "Influence of clenbuterol on mucociliary transport in healthy horses and horses with chronic obstructive pulmonary disease."
07/01/2002 - "In a placebo-controlled drug study data were collected about flow, volume and expiratory CO2-concentration in 13 horses with chronic obstructive pulmonary disease before and until 2.5 h after intravenous injection of clenbuterol. "
|5.||Muscular Atrophy (Muscle Atrophy)
01/01/2011 - "Randomized, double-blind, and placebo-controlled trial of clenbuterol in denervated muscle atrophy."
07/01/2001 - "The attenuated muscle atrophy found with clenbuterol in the present study provides cellular evidence for the reported change in muscle strength after its administration after knee surgery. "
07/01/2001 - "Clenbuterol in the prevention of muscle atrophy: a study of hindlimb-unweighted rats."
05/01/2012 - "They then evaluated the effects of 8 weeks of treadmill training in Tx mice that received BCD or BCD + clenbuterol, a monoaminergic agent with anabolic properties, on locomotor function, muscle atrophy, adipose tissue loss, and bone density measures. "
02/01/2007 - "Clenbuterol and other beta2-adrenergic agonists are effective at inducing muscle growth and attenuating muscle atrophy through unknown mechanisms. "
|4.||Adrenergic Receptors (Adrenergic Receptor)
|6.||Myosin Heavy Chains (Myosin Heavy Chain)
|9.||Alendronate (Alendronate Sodium)
|10.||beta Adrenergic Receptors
|2.||Enzyme Replacement Therapy
|3.||Prostatectomy (Retropubic Prostatectomy)